KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

David J Kuter, Waleed Ghanima, Nichola Cooper, Howard A Liebman, Lei Zhang, Yu Hu, Yoshitaka Miyakawa, Wojciech Homenda, Luisa Elena Morales Galindo, Ana Lisa Basquiera, Chuen Wen Tan, Guray Saydam, Marie Luise Hütter-Krönke, Chatree Chai-Adisaksopha, David Gómez-Almaguer, Huy Tran, Ho-Jin Shin, Ademar Dantas da Cunha Junior, Zsolt Lazar, Cristina Pascual Izquierdo, Ilya Kirgner, Elisa Lucchini, Ganna Kuzmina, Michael Fillitz, Sylvain Audia, Minakshi Taparia, Matias Cordoba, Remco Diab, Mengjie Yao, Imene Gouia, Michelle Lee, Ahmed Daak

Blood 145(24) 2914-2926

PMID40090011
PMCIDPMC12824683
DOI10.1182/blood.2024027336
发表日期2025-03-16
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo (n = 69) for 24 weeks. At baseline overall, median age was 47 years, 63% female, 7.7 year median ITP duration, and 28% prior splenectomy. Overall (N = 202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50 × 109/L or 30 × 109/L to <50 × 109/L and doubled from baseline) during the first 12 weeks and were eligible to continue. The primary end point, durable platelet response (platelet count ≥50 × 109/L for ≥two-thirds of ≥8 of the last 12 of 24 weeks without rescue therapy), was observed in 31 (23%) rilzabrutinib vs 0 placebo patients (P < .0001). All secondary efficacy end points were significantly superior for rilzabrutinib (P < .05). Median time to first platelet response was 15 days in rilzabrutinib responders. Rilzabrutinib significantly reduced rescue therapy use by 52% (P = .0007) and improved week 25 bleeding scores (P = .0006). Improved physical fatigue was sustained from week 13 (P = .01) through 25 (P = .0003). Treatment-related adverse events were mainly grade 1/2. One rilzabrutinib patient with multiple risk factors had serious treatment-related grade 3 peripheral embolism (lower left leg), and another died from unrelated pneumonia. Rilzabrutinib in patients who failed multiple previous ITP therapies showed rapid and durable platelet response, reduced rescue medication and bleeding, improved physical fatigue, and favorable safety. Trial registration: www.clinicaltrials.gov (#NCT04562766) and www.clinicaltrialsregister.eu (#2020-002063-60).

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 3

Figure 3. Time to event analyses. Kaplan-Meier plot of time to first platelet count of ≥50 × 10 9 /L or ≥30 × 10 9 /L and doubled from baseline (A) and time to first use of rescue therapy (B) during the 24-week double-blind period. Cox regression model was used with treatment group and stratification factors as covariates. Log-rank test was adjusted by stratification factors.

A

Time to first platelet count of ≥50 × 10⁹/L or ≥30 × 10⁹/L and doubled from baseline

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Time to first use of rescue therapy

Figure 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. CONSORT flow diagram. ∗After 12 weeks, responders with platelet count of ≥50 × 10 9 /L or 30 × 10 9 /L to <50 × 10 9 /L and at least doubled from baseline (referred to as “platelet response”) could continue blinded treatment; nonresponders could discontinue or enter the 28-week open-label period receiving rilzabrutinib 400 mg twice daily (initial treatment remained blinded). Patients who discontinued the 24-week double-blind period because of lack of response were given the option to enter the 28-week open-label period. †Includes patients who have entered as of the data cutoff. All patients in the 28-week open-label and long-term extension periods received rilzabrutinib 400 mg twice daily despite their initial treatment arm assignment. ‡Included 1 patient who discontinued because of an AE of pneumonia that was deemed unrelated to treatment per investigator judgment and lasted 16 days before rilzabrutinib was discontinued and the patient died (see the supplemental Safety Results for details). bid, twice daily.
非 KM Figure
Figure 2Figure 2. Platelet counts and subgroup analyses. Median platelet counts (IQR) over time for rilzabrutinib vs placebo arms (A) and by responder status (B), and subgroup analysis of durable responses (C). Durable platelet response was defined as the proportion of patients achieving platelet counts of ≥50 × 10 9 /L for two-thirds or more of at least 8 nonmissing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 nonmissing weekly platelet measurements were ≥50 × 10 9 /L during the last 6 weeks of the 24-week blinded treatment period. Vertical dashed line at week 13 represents measurement of patient response and continuation of responders to treatment through 24 weeks. IQR, interquartile range; y, year.
非 KM Figure
Figure 4Figure 4. Physical fatigue and bleeding scores. Mean change (SE) from baseline on physical fatigue (item 10 of the ITP-PAQ) (A), and mean change (SE) from baseline in IBLS (B) during the 24-week double-blind period. Vertical dashed line at week 13 represents measurement of patient response and continuation of responders to treatment through 24 weeks.
非 KM Figure